109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
司库奇尤单抗成功治疗合并血液透析的终末期肾病红皮病型银屑病患者 ——1 例病例报告
Authors Zhang S, Liu P, Liu S, He M, Zheng S, Sun X, Qi R, Gao X, Zhu L
Received 5 June 2025
Accepted for publication 21 October 2025
Published 27 October 2025 Volume 2025:18 Pages 2829—2833
DOI https://doi.org/10.2147/CCID.S545123
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jeffrey Weinberg
摘要： 红皮病型银屑病合并需血液透析的终末期肾病患者在临床中极为罕见，针对该特定人群的治疗选择仍非常有限。本文报告 1 例此类患者，采用白细胞介素 - 17（IL-17）抑制剂司库奇尤单抗治疗后，不仅快速缓解了红皮病症状，还使肾功能得到一定程度改善。随访 7 个月时，患者皮损持续清除且肾功能未出现恶化 —— 这一结果在以往文献中尚未有一致报道。该病例提示，对于合并肾病的银屑病患者，IL-17 抑制剂可能是一种潜在的优选治疗方案。